Amerikanische Gesellschaft für Hirudotherapie

A network pharmacology-based study on the mechanism of hirudin attenuates renal interstitial fibrosis through Nrf2 and NF-κB signalling pathways

Mechanism study published in Naunyn-Schmiedeberg's Archives of Pharmacology (2026)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportSicherheit & InfektionskontrolleArzneimittelentwicklungYang K et al. · Naunyn-Schmiedeberg's archives of pharmacology, 2026

Abstract

This study was aimed at elucidating the therapeutic effects of hirudin on renal interstitial fibrosis (RIF) and at delineating the molecular mechanisms underlying its antifibrotic actions. A comprehensive research approach was adopted, integrating network pharmacology, molecular docking, molecular dynamics simulations, and in vitro experimental validation, to explore the mechanisms through which hirudin alleviates RIF. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis identified 185 enriched signalling pathways, with the primary ones being the VEGF signalling pathway, TNFA signalling pathway and NF-κB signalling pathway. Gene Ontology (GO) analysis revealed that hirudin's antifibrotic effects were associated with inflammatory responses, canonical NF-κB signal transduction, and cellular responses to oxidative stress. Protein-protein interaction (PPI) network analysis identified TNF, HIF1A, HO-1, CASP3, IKBA, KEAP1, and RELA as key hub proteins. Experimental validation demonstrated that hirudin significantly reduced the protein levels of fibronectin (FN) and collagen I (Col I) in TGF-β1-stimulated HK-2 cells. Additionally, hirudin downregulated pro-inflammatory markers (TNF-α, MCP-1, p-P65, and p-IκBα) while upregulating antioxidant proteins (Nrf2, HO-1, and SOD-1). These findings suggest that hirudin mitigates TGF-β1-induced inflammation and oxidative stress in HK-2 cells by modulating the Nrf2 and NF-κB signalling pathways, thereby impeding the progression of RIF.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsNF-E2-Related Factor 2HumansSignal TransductionFibrosisNF-kappa BNetwork PharmacologyHirudinsCell LineMolecular Docking SimulationKidney DiseasesKidneyProtein Interaction Maps

Zusammenfassung

Network pharmacology and in vivo validation showing leech-derived hirudin attenuates renal interstitial fibrosis via Nrf2 and NF-κB signaling pathways — extends hirudin into nephrology.

Warum dies für die Hirudotherapie relevant ist

This study used network pharmacology, molecular docking, molecular dynamics simulations, and in vitro experiments to investigate how hirudin attenuates renal interstitial fibrosis (RIF) by modulating the Nrf2 and NF-κB signaling pathways. Hirudin reduced fibrosis markers (fibronectin, collagen I) and pro-inflammatory markers while upregulating antioxidant proteins in TGF-β1-stimulated HK-2 cells, suggesting it mitigates inflammation and oxidative stress. The abstract does not describe hirudin as leech-derived, nor does it reference traditional anticoagulant use or hirudotherapy, so the relevance to ASH is limited to the pharmacological study of a compound named hirudin. The main caveat is that findings are based on computational analysis and a cultured cell line, with no human or animal data.

Zitation

A network pharmacology-based study on the mechanism of hirudin attenuates renal interstitial fibrosis through Nrf2 and NF-κB signalling pathways.

Yang K et al. · Naunyn-Schmiedeberg's archives of pharmacology, 2026

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.